Lithium, a cornerstone therapy for bipolar disorder (BD), produces complex and dual effects on cardiovascular health. This review synthesizes current evidence on the direct and indirect cardiovascular effects of lithium. Direct effects include dose-dependent influences on cardiac development, hypertrophy, fibrosis, mitochondrial function, and arrhythmia. While therapeutic doses may confer cardioprotective benefits by inhibiting GSK-3β, which activates the Wnt/β-catenin signaling pathway and modulates anti-inflammatory pathways, supratherapeutic levels exacerbate oxidative stress, mitochondrial dysfunction, and arrhythmogenicity. Indirectly, lithium modulates cardiovascular outcomes caused by renal dysfunction, metabolic syndrome, and neuroendocrine-immune interactions. Clinical studies suggested that there is reduced cardiovascular mortality in lithium-treated BD patients, potentially offsetting its adverse metabolic effects. However, conflicting evidence persists, particularly regarding dose specificity and long-term outcomes. Future research should focus on high-quality clinical trials to clarify the balance between therapeutic benefits and adverse effects of lithium to ensure its safe and effective use in clinical practice.
Lithium in cardiovascular health and disease: Pharmacological and clinical implications.
Jingya Jiang,Wanbing He,Hui Huang
Published 2025 in European Journal of Pharmacology
ABSTRACT
PUBLICATION RECORD
- Publication year
2025
- Venue
European Journal of Pharmacology
- Publication date
2025-05-01
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
CITED BY
Showing 1-3 of 3 citing papers · Page 1 of 1